Phase 3 results are promising for Aimmune

California based biotech company, Aimmune, has presented strong phase 3 trial data for its peanut allergy treatment, AR101.

The 12-month study, which enrolled nearly 500 children who are intolerant to peanut protein showed promising results. Each child was randomized to receive AR101 or placebo. After a 22-week dose escalation phase, participants continued to take 300mg a day of peanut flour AR101 or placebo until the end of the study.

More than 2/3 of the patients on AR101 tolerated 600mg (about two peanuts or a small bite of a peanut butter sandwich) or more of peanut protein compared to only 4% in the control group.

There are, however, some concerns with the safety data as about one-fifth of the participants dropped out of the study siting adverse events such as GI issues and systemic hypersensitivity as the reason for leaving.

Click here to view the entire article.